[go: up one dir, main page]

EP3704239A4 - Compositions de casz et procédés d'utilisation - Google Patents

Compositions de casz et procédés d'utilisation Download PDF

Info

Publication number
EP3704239A4
EP3704239A4 EP18874900.6A EP18874900A EP3704239A4 EP 3704239 A4 EP3704239 A4 EP 3704239A4 EP 18874900 A EP18874900 A EP 18874900A EP 3704239 A4 EP3704239 A4 EP 3704239A4
Authority
EP
European Patent Office
Prior art keywords
casz
compositions
casz compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18874900.6A
Other languages
German (de)
English (en)
Other versions
EP3704239A1 (fr
Inventor
Jennifer A. Doudna
David Burstein
Janice S. Chen
Lucas B. HARRINGTON
David PAEZ-ESPINO
Jillian F. Banfield
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California, University of California Berkeley, University of California San Diego UCSD filed Critical University of California
Publication of EP3704239A1 publication Critical patent/EP3704239A1/fr
Publication of EP3704239A4 publication Critical patent/EP3704239A4/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1003—Transferases (2.) transferring one-carbon groups (2.1)
    • C12N9/1007—Methyltransferases (general) (2.1.1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/301—Endonuclease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP18874900.6A 2017-11-01 2018-10-31 Compositions de casz et procédés d'utilisation Pending EP3704239A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762580395P 2017-11-01 2017-11-01
PCT/US2018/058545 WO2019089820A1 (fr) 2017-11-01 2018-10-31 Compositions de casz et procédés d'utilisation

Publications (2)

Publication Number Publication Date
EP3704239A1 EP3704239A1 (fr) 2020-09-09
EP3704239A4 true EP3704239A4 (fr) 2021-08-18

Family

ID=66332730

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18874900.6A Pending EP3704239A4 (fr) 2017-11-01 2018-10-31 Compositions de casz et procédés d'utilisation

Country Status (14)

Country Link
US (10) US20200087640A1 (fr)
EP (1) EP3704239A4 (fr)
JP (2) JP2021503278A (fr)
KR (1) KR20200091858A (fr)
CN (2) CN111886336B (fr)
AU (1) AU2018358051B2 (fr)
BR (1) BR112020008654A2 (fr)
CA (1) CA3080493A1 (fr)
GB (1) GB2582482B (fr)
IL (1) IL274276A (fr)
MX (1) MX2020004578A (fr)
RU (1) RU2020117711A (fr)
SG (1) SG11202003863VA (fr)
WO (1) WO2019089820A1 (fr)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010101628A2 (fr) 2009-03-02 2010-09-10 Massachusetts Institute Of Technology Procédés et produits pour établir un profil enzymatique in vivo
WO2012125808A1 (fr) 2011-03-15 2012-09-20 Massachusetts Institute Of Technology Détection multiplexée avec rapporteurs contenant un isotope d'identification
CN105452481A (zh) 2013-06-07 2016-03-30 麻省理工学院 基于亲和力检测配体编码的合成性生物标记物
US20180250424A1 (en) 2014-10-10 2018-09-06 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
EP3440013A4 (fr) 2016-04-08 2021-03-17 Massachusetts Institute of Technology Procédés pour profiler spécifiquement l'activité de la protéase au niveau de ganglions lymphatiques
EP3452407B1 (fr) 2016-05-05 2024-04-03 Massachusetts Institute Of Technology Méthodes et utilisations aux fins de mesures d'activité protéasique déclenchées à distance
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
WO2018064371A1 (fr) 2016-09-30 2018-04-05 The Regents Of The University Of California Nouvelles enzymes de modification d'acides nucléiques guidées par arn et leurs méthodes d'utilisation
KR102812752B1 (ko) 2016-09-30 2025-05-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
WO2018119010A1 (fr) 2016-12-19 2018-06-28 Editas Medicine, Inc. Évaluation du clivage de nucléases
US12110545B2 (en) 2017-01-06 2024-10-08 Editas Medicine, Inc. Methods of assessing nuclease cleavage
CA3059358A1 (fr) 2017-04-07 2018-10-11 Massachusetts Institute Of Technology Procedes de profilage spatial d'activite protease dans un tissu et des coupes
EP3615672A1 (fr) 2017-04-28 2020-03-04 Editas Medicine, Inc. Procédés et systèmes d'analyse de molécules d'arn
CN110997908A (zh) 2017-06-09 2020-04-10 爱迪塔斯医药公司 工程化的cas9核酸酶
WO2019014564A1 (fr) 2017-07-14 2019-01-17 Editas Medicine, Inc. Systèmes et procédés d'intégration ciblée et d'édition du génome et détection de celle-ci à l'aide de sites d'amorçage intégrés
WO2019089804A1 (fr) 2017-11-01 2019-05-09 The Regents Of The University Of California Compositions de casy et procédés d'utilisation
AU2018358051B2 (en) 2017-11-01 2025-01-09 The Regents Of The University Of California CasZ compositions and methods of use
US11970719B2 (en) 2017-11-01 2024-04-30 The Regents Of The University Of California Class 2 CRISPR/Cas compositions and methods of use
EP3755792A4 (fr) 2018-02-23 2021-12-08 Pioneer Hi-Bred International, Inc. Nouveaux orthologues de cas9
CN110551800B (zh) * 2018-06-03 2022-08-19 上海吐露港生物科技有限公司 一种耐高温Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒
CA3104856A1 (fr) 2018-06-29 2020-01-02 Editas Medicine, Inc. Molecules de guidage synthetiques, compositions et procedes associes
EP4442836A3 (fr) 2018-08-01 2024-12-18 Mammoth Biosciences, Inc. Compositions de nucléase programmable et leurs procédés d'utilisation
EP3844303A4 (fr) * 2018-08-27 2022-06-01 The Regents of The University of California Acides nucléiques rapporteurs pour une détection médiée par crispr de type v
US12173349B2 (en) 2018-09-25 2024-12-24 Massachusetts Institute Of Technology Lung protease nanosensors and uses thereof
US10934536B2 (en) 2018-12-14 2021-03-02 Pioneer Hi-Bred International, Inc. CRISPR-CAS systems for genome editing
EP3931313A2 (fr) 2019-01-04 2022-01-05 Mammoth Biosciences, Inc. Améliorations de nucléase programmable ainsi que compositions et méthodes d'amplification et de détection d'acide nucléique
WO2020150560A1 (fr) 2019-01-17 2020-07-23 Massachusetts Institute Of Technology Capteurs pour détecter et imager une métastase cancéreuse
WO2020181101A1 (fr) 2019-03-07 2020-09-10 The Regents Of The University Of California Polypeptides effecteurs crispr-cas et procédés d'utilisation associés
WO2020223634A1 (fr) * 2019-05-01 2020-11-05 Mammoth Biosciences, Inc. Nucléases programmables et procédés d'utilisation
JP2022536364A (ja) 2019-06-13 2022-08-15 ザ ジェネラル ホスピタル コーポレイション 操作されたヒト内在性ウイルス様粒子および細胞への送達のためのその使用方法
CN114846146B (zh) 2019-10-29 2024-04-12 基恩科雷有限责任公司 用于增加CRISPR/Cas12f1系统的效率的工程化引导RNA及其用途
US20210262025A1 (en) 2020-02-18 2021-08-26 Massachusetts Institute Of Technology Multiplexed in vivo disease sensing with nucleic acid-barcoded reporters
CN111257297B (zh) * 2020-03-31 2023-06-16 海南大学 一种基于Cas14a酶的RNA检测方法
EP4133069A2 (fr) 2020-04-08 2023-02-15 Astrazeneca AB Compositions et procédés pour modification améliorée spécifique d'un site
WO2022020800A2 (fr) 2020-07-24 2022-01-27 The General Hospital Corporation Pseudo-particules virales améliorées et leurs méthodes d'utilisation pour l'administration à des cellules
EP4208545A4 (fr) 2020-09-01 2024-10-30 The Board of Trustees of the Leland Stanford Junior University Système crispr-cas miniature synthétique (casmini) pour ingénierie génomique eucaryote
US10894812B1 (en) 2020-09-30 2021-01-19 Alpine Roads, Inc. Recombinant milk proteins
IL301396A (en) 2020-09-30 2023-05-01 Nobell Foods Inc Recombinant milk proteins and food compositions comprising the same
US10947552B1 (en) 2020-09-30 2021-03-16 Alpine Roads, Inc. Recombinant fusion proteins for producing milk proteins in plants
KR102638799B1 (ko) * 2020-10-08 2024-02-22 주식회사 진코어 CRISPR/Cas12f1(Cas14a1) system 효율화를 위한 engineered guide RNA 및 이의 용도
CN116568803A (zh) 2020-10-08 2023-08-08 基恩科雷有限责任公司 用于增加CRISPR/Cas12f1系统的效率的包含富含U的尾部的经工程化的引导RNA及其用途
US20230374500A1 (en) * 2020-10-08 2023-11-23 Genkore Inc. Engineered guide rna comprising u-rich tail for optimized crispr/cas12f1 system and use thereof
US20230416784A1 (en) * 2020-10-08 2023-12-28 Genkore Inc. Engineered guide rna for optimized crispr/cas12f1 (cas14a1) system and use thereof
EP4227411A4 (fr) * 2020-10-08 2025-07-09 Genkore Inc Arn guide modifié pour augmenter l'efficacité du système crispr/cas12f1, et son utilisation
KR102758158B1 (ko) * 2021-04-21 2025-01-23 주식회사 진코어 CRISPR/Cas12f1 시스템 효율화를 위한 엔지니어링 된 가이드 RNA 및 그 용도
CN112176035A (zh) * 2020-10-14 2021-01-05 杭州优思达生物技术有限公司 一种新型crispr核酸检测方法及应用
US20250340854A1 (en) * 2020-10-30 2025-11-06 The University Of Tokyo ENGINEERED Cas12f PROTEIN
CN116334037A (zh) * 2020-11-11 2023-06-27 山东舜丰生物科技有限公司 新型Cas酶和系统以及应用
EP4337701A4 (fr) 2021-05-10 2025-04-09 Mammoth Biosciences, Inc. Protéines effectrices et leurs méthodes d'utilisation
WO2022241032A1 (fr) * 2021-05-12 2022-11-17 Mammoth Biosciences, Inc. Acides nucléiques guides améliorés et méthodes d'utilisation
KR20220155553A (ko) 2021-05-14 2022-11-23 주식회사 진코어 RNA-guided Nuclease를 이용한 LCA10 치료용 조성물 및 치료방법
WO2022256440A2 (fr) 2021-06-01 2022-12-08 Arbor Biotechnologies, Inc. Systèmes d'édition de gènes comprenant une nucléase crispr et leurs utilisations
EP4368713A4 (fr) 2021-07-05 2025-10-08 Genkore Inc Cas12f1 à clivage inactif, protéine de fusion à base de cas12f1 à clivage inactif, système d'édition génique crispr les comprenant, procédé de préparation et utilisation de ceux-ci
US12139731B2 (en) 2021-07-08 2024-11-12 National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) U.S. Government CRISPR-based programmable RNA editing
EP4373963A4 (fr) 2021-07-21 2025-06-18 Montana State University Détection d'acide nucléique à l'aide d'un complexe crispr de type iii
WO2023086938A2 (fr) * 2021-11-12 2023-05-19 Arbor Biotechnologies, Inc. Nucléases de type v
EP4441074A2 (fr) 2021-12-03 2024-10-09 The Broad Institute, Inc. Compositions et méthodes pour administration in vivo efficace
KR20240152394A (ko) 2022-03-01 2024-10-21 에피크리스피알 바이오테크놀로지스, 인크. 조작된 뉴클레아제, 그의 조성물 및 사용 방법
KR20230134097A (ko) 2022-03-10 2023-09-20 주식회사 진코어 Nhej 복구 경로 조절을 통해 핵산 세그먼트의 결실 효율을 증가시키기 위한 조성물 및 방법
CN114561456A (zh) * 2022-03-23 2022-05-31 北京盛因生物科技有限公司 一种等温核酸检测酶组合物、试剂盒及其用途和检测方法
WO2023191570A1 (fr) 2022-03-30 2023-10-05 주식회사 진코어 Système d'édition génique pour le traitement du syndrome d'usher
US20250250616A1 (en) * 2022-04-13 2025-08-07 The Board Of Trustees Of The Leland Stanford Junior University Enzyme kinetics analyses of crispr endonucleases
WO2023208000A1 (fr) * 2022-04-25 2023-11-02 Huidagene Therapeutics Co., Ltd. Nouveaux systèmes crispr-cas12f et leurs utilisations
WO2023225572A2 (fr) 2022-05-17 2023-11-23 Nvelop Therapeutics, Inc. Compositions et méthodes pour administration in vivo efficace
US12435357B2 (en) 2022-12-22 2025-10-07 Kanso Diagnostics Ltd. Diagnostic device for detecting a target nucleic acid molecule in a biological sample
WO2024145743A1 (fr) * 2023-01-03 2024-07-11 哈尔滨工业大学 Système d'endonucléase guidée par l'arn et son application à l'édition génique
WO2024173645A1 (fr) 2023-02-15 2024-08-22 Arbor Biotechnologies, Inc. Procédé d'édition génique pour inhiber l'épissage aberrant du transcrit de la stathmine 2 (stmn2)
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025019273A1 (fr) * 2023-07-14 2025-01-23 Epicrispr Biotechnologies, Inc. Nucléases modifiées et séquences d'espacement d'arn guide associées, compositions et procédés d'utilisation associés
WO2025049959A2 (fr) 2023-09-01 2025-03-06 Renagade Therapeutics Management Inc. Systèmes et compositions d'édition génique, et méthodes de traitement du syndrome vexas
CN117512071B (zh) * 2023-09-15 2024-06-04 湖北大学 一种耐高温TnpB蛋白及其在核酸检测中的应用
WO2025067172A1 (fr) * 2023-09-25 2025-04-03 山东舜丰生物科技有限公司 Nouvelle enzyme crispr, système et application
WO2025171210A1 (fr) 2024-02-09 2025-08-14 Arbor Biotechnologies, Inc. Compositions et procédés d'édition de gènes par l'intermédiaire d'une jonction d'extrémité à médiation par homologie
WO2025174765A1 (fr) 2024-02-12 2025-08-21 Renagade Therapeutics Management Inc. Nanoparticules lipidiques comprenant des molécules d'arn codant destinées à être utilisées dans l'édition génique et comme vaccins et agents thérapeutiques
CN119162153B (zh) * 2024-11-22 2025-02-07 镁孚泰生物科技(上海)有限公司 Cas12f核酸酶突变体、其应用及试剂盒
CN119776330B (zh) * 2025-01-10 2025-06-10 西北农林科技大学 一种胞嘧啶脱氨编辑器及编辑系统

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001090337A2 (fr) 2000-05-24 2001-11-29 Third Wave Technologies, Inc. Detection d'arn
US6773885B1 (en) 2000-09-29 2004-08-10 Integrated Dna Technologies, Inc. Compositions and methods for visual ribonuclease detection assays
CN1886512A (zh) 2002-04-23 2006-12-27 斯克里普斯研究所 多肽在叶绿体中的表达以及用于表达多肽的组合物和方法
EP1580273A1 (fr) * 2004-03-26 2005-09-28 Friedrich-Alexander-Universität Erlangen-Nürnberg Méthode à base de peptides pour suivre l'expression génétique dans une cellule hôte
ZA200803368B (en) * 2005-10-07 2009-09-30 Univ California Nucleic acids encoding modified cytochrome P450 enzymes and methods of use thereof
US9689031B2 (en) 2007-07-14 2017-06-27 Ionian Technologies, Inc. Nicking and extension amplification reaction for the exponential amplification of nucleic acids
WO2011100749A2 (fr) 2010-02-15 2011-08-18 Cascade Biosystems, Inc. Procédés et matériaux de détection d'infections virales ou microbiennes
SG186987A1 (en) 2010-06-11 2013-02-28 Pathogenica Inc Nucleic acids for multiplex organism detection and methods of use and making the same
US9730967B2 (en) 2011-02-04 2017-08-15 Katherine Rose Kovarik Method and system for treating cancer cachexia
US8815782B2 (en) 2011-11-11 2014-08-26 Agilent Technologies, Inc. Use of DNAzymes for analysis of an RNA sample
RS59199B1 (sr) 2012-05-25 2019-10-31 Univ California Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta
KR102479178B1 (ko) 2012-12-06 2022-12-19 시그마-알드리치 컴퍼니., 엘엘씨 Crispr-기초된 유전체 변형과 조절
JP2016505256A (ja) 2012-12-12 2016-02-25 ザ・ブロード・インスティテュート・インコーポレイテッ 配列操作のためのＣＲＩＳＰＲ−Ｃａｓ成分系、方法および組成物
NZ712727A (en) * 2013-03-14 2017-05-26 Caribou Biosciences Inc Compositions and methods of nucleic acid-targeting nucleic acids
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US10704060B2 (en) * 2013-06-05 2020-07-07 Duke University RNA-guided gene editing and gene regulation
US20160298096A1 (en) 2013-11-18 2016-10-13 Crispr Therapeutics Ag Crispr-cas system materials and methods
US9994831B2 (en) 2013-12-12 2018-06-12 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
US9850525B2 (en) 2014-01-29 2017-12-26 Agilent Technologies, Inc. CAS9-based isothermal method of detection of specific DNA sequence
CA2942915A1 (fr) 2014-03-20 2015-09-24 Universite Laval Methodes crispr et produits pouvant augmenter les taux de frataxine et leurs utilisations
EP3129488B1 (fr) * 2014-04-10 2019-06-12 The Regents of The University of California Procédés et compositions pour l'utilisation d'un argonaute pour modifier un acide nucléique simple brin cible
WO2015191693A2 (fr) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Procédé d'édition génique
US20180320226A1 (en) * 2014-08-19 2018-11-08 President And Fellows Of Harvard College RNA-Guided Systems For Probing And Mapping Of Nucleic Acids
EP3985115A1 (fr) 2014-12-12 2022-04-20 The Broad Institute, Inc. Arn guides protégés (pgrnas)
WO2016094872A1 (fr) 2014-12-12 2016-06-16 The Broad Institute Inc. Guides désactivés pour facteurs de transcription crispr
WO2016106236A1 (fr) 2014-12-23 2016-06-30 The Broad Institute Inc. Système de ciblage d'arn
EP3250689B1 (fr) 2015-01-28 2020-11-04 The Regents of The University of California Procédés et compositions pour le marquage d'un acide nucléique cible monocaténaire
GB201506509D0 (en) 2015-04-16 2015-06-03 Univ Wageningen Nuclease-mediated genome editing
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
CA3012607A1 (fr) 2015-06-18 2016-12-22 The Broad Institute Inc. Enzymes et systemes crispr
JP7107683B2 (ja) 2015-06-18 2022-07-27 ザ・ブロード・インスティテュート・インコーポレイテッド オフターゲット効果を低下させるｃｒｉｓｐｒ酵素突然変異
CA3012631A1 (fr) 2015-06-18 2016-12-22 The Broad Institute Inc. Nouvelles enzymes crispr et systemes associes
US9580727B1 (en) * 2015-08-07 2017-02-28 Caribou Biosciences, Inc. Compositions and methods of engineered CRISPR-Cas9 systems using split-nexus Cas9-associated polynucleotides
US12234454B2 (en) 2015-10-22 2025-02-25 The Broad Institute, Inc. Crispr enzymes and systems
WO2017120410A1 (fr) * 2016-01-08 2017-07-13 University Of Georgia Research Foundation, Inc. Procédés de clivage des molécules d'adn et d'arn
US11441146B2 (en) 2016-01-11 2022-09-13 Christiana Care Health Services, Inc. Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system
US9896696B2 (en) 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
US20190024075A1 (en) 2016-02-23 2019-01-24 Arc Bio, Llc Methods and compositions for target detection
WO2017176529A1 (fr) 2016-04-06 2017-10-12 Temple Univesity-Of The Commonwealth System Of Higher Education Compositions pour éradiquer des infections à flavivirus chez des sujets
US11371081B2 (en) 2016-05-25 2022-06-28 Arizona Board Of Regents On Behalf Of Arizona State University Portable, low-cost pathogen detection and strain identification platform
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
CA3028158A1 (fr) 2016-06-17 2017-12-21 The Broad Institute, Inc. Systemes et orthologues crispr de type vi
AU2017280353B2 (en) 2016-06-24 2021-11-11 Inscripta, Inc. Methods for generating barcoded combinatorial libraries
US12431216B2 (en) 2016-08-17 2025-09-30 Broad Institute, Inc. Methods for identifying class 2 crispr-cas systems
WO2018064371A1 (fr) 2016-09-30 2018-04-05 The Regents Of The University Of California Nouvelles enzymes de modification d'acides nucléiques guidées par arn et leurs méthodes d'utilisation
KR102812752B1 (ko) 2016-09-30 2025-05-26 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Rna-가이드된 핵산 변형 효소 및 이의 사용 방법
CN106701830B (zh) * 2016-12-07 2020-01-03 湖南人文科技学院 一种敲除猪胚胎p66shc基因的方法
DK3551753T3 (da) 2016-12-09 2022-09-05 Broad Inst Inc Diagnostik baseret på crispr-effektorsystem
WO2018172556A1 (fr) 2017-03-24 2018-09-27 Curevac Ag Acides nucléiques codant pour des protéines associées à crispr et leurs utilisations
CN110799525A (zh) 2017-04-21 2020-02-14 通用医疗公司 具有改变的PAM特异性的CPF1(CAS12a)的变体
BR112020002647A2 (pt) * 2017-08-09 2020-08-18 Benson Hill, Inc. composições e métodos para modificação de genomas
AU2018358051B2 (en) 2017-11-01 2025-01-09 The Regents Of The University Of California CasZ compositions and methods of use
WO2019089804A1 (fr) 2017-11-01 2019-05-09 The Regents Of The University Of California Compositions de casy et procédés d'utilisation
EP3704254A4 (fr) 2017-11-01 2021-09-01 The Regents of The University of California Compositions de cas12c et procédés d'utilisation
US11970719B2 (en) 2017-11-01 2024-04-30 The Regents Of The University Of California Class 2 CRISPR/Cas compositions and methods of use
US10253365B1 (en) * 2017-11-22 2019-04-09 The Regents Of The University Of California Type V CRISPR/Cas effector proteins for cleaving ssDNAs and detecting target DNAs
CN111836903A (zh) 2017-12-22 2020-10-27 博德研究所 基于crispr效应系统的多重诊断
CN116568803A (zh) * 2020-10-08 2023-08-08 基恩科雷有限责任公司 用于增加CRISPR/Cas12f1系统的效率的包含富含U的尾部的经工程化的引导RNA及其用途

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JANICE S. CHEN ET AL: "CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity", SCIENCE, vol. 360, no. 6387, 27 April 2018 (2018-04-27), US, pages 436 - 439, XP055615609, ISSN: 0036-8075, DOI: 10.1126/science.aar6245 *
LIU CHANG ET AL: "Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 266, 11 September 2017 (2017-09-11), pages 17 - 26, XP085292687, ISSN: 0168-3659, DOI: 10.1016/J.JCONREL.2017.09.012 *
LUCAS B. HARRINGTON ET AL: "Programmed DNA destruction by miniature CRISPR-Cas14 enzymes", SCIENCE, vol. 362, no. 6416, 16 November 2018 (2018-11-16), US, pages 839 - 842, XP055614750, ISSN: 0036-8075, DOI: 10.1126/science.aav4294 *
MAKAROVA KIRA S ET AL: "Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and derived variants", NATURE REVIEWS MICROBIOLOGY, NATURE PUBLISHING GROUP, GB, vol. 18, no. 2, 19 December 2019 (2019-12-19), pages 67 - 83, XP036990744, ISSN: 1740-1526, [retrieved on 20191219], DOI: 10.1038/S41579-019-0299-X *
See also references of WO2019089820A1 *
SERGEY SHMAKOV ET AL: "Diversity and evolution of class 2 CRISPR-Cas systems", NATURE REVIEWS MICROBIOLOGY, vol. 15, no. 3, 30 March 2017 (2017-03-30), GB, pages 169 - 182, XP055718298, ISSN: 1740-1526, DOI: 10.1038/nrmicro.2016.184 *

Also Published As

Publication number Publication date
CN111886336B (zh) 2025-05-02
GB2582482A (en) 2020-09-23
JP7672445B2 (ja) 2025-05-07
US20240167009A1 (en) 2024-05-23
US20210017508A1 (en) 2021-01-21
BR112020008654A2 (pt) 2020-11-10
RU2020117711A (ru) 2021-12-02
KR20200091858A (ko) 2020-07-31
AU2018358051B2 (en) 2025-01-09
US11180743B2 (en) 2021-11-23
US20250179470A1 (en) 2025-06-05
US20250207152A1 (en) 2025-06-26
CN111886336A (zh) 2020-11-03
US20230323319A1 (en) 2023-10-12
EP3704239A1 (fr) 2020-09-09
IL274276A (en) 2020-06-30
MX2020004578A (es) 2020-12-03
US20200087640A1 (en) 2020-03-19
GB2582482B (en) 2023-05-17
RU2020117711A3 (fr) 2022-03-28
US11441137B2 (en) 2022-09-13
US20200299660A1 (en) 2020-09-24
US12264314B1 (en) 2025-04-01
US20200172886A1 (en) 2020-06-04
CA3080493A1 (fr) 2019-05-09
WO2019089820A1 (fr) 2019-05-09
US11453866B2 (en) 2022-09-27
US11371031B2 (en) 2022-06-28
JP2021503278A (ja) 2021-02-12
GB202008124D0 (en) 2020-07-15
US20200370028A1 (en) 2020-11-26
SG11202003863VA (en) 2020-05-28
CN117487776A (zh) 2024-02-02
AU2018358051A1 (en) 2020-05-14
JP2023082141A (ja) 2023-06-13

Similar Documents

Publication Publication Date Title
EP3704239A4 (fr) Compositions de casz et procédés d'utilisation
EP3704254A4 (fr) Compositions de cas12c et procédés d'utilisation
EP3310378C0 (fr) Anticorps anti-c1 et leurs procédés d'utilisation
EP3970680C0 (fr) Station de technologie médicale et procédé d'utilisation
EP3576782A4 (fr) Compositions de produit de recombinaison-peptide et leurs méthodes d'utilisation
EP3749343A4 (fr) Formulation et procédé d'utilisation
EP3583406C0 (fr) Biocapteur plamo-photonique intégré et procédé d'utilisation
EP3565520A4 (fr) Compositions anhydres d'inhibiteurs de mtor et méthodes d'utilisation
EP3600372A4 (fr) Compositions de synthékine et procédés d'utilisation
EP3691677A4 (fr) Compositions de conjugués saccharide-polypeptide et leurs procédés d'utilisation
EP3630949A4 (fr) Compositions et procédés d'obtention d'organoïdes
EP3761972A4 (fr) Compositions bioréactives et leurs procédés d'utilisation
EP3585426A4 (fr) Compositionset méthodes de transduction tumorale
EP3634390A4 (fr) Compositions antimicrobiennes comprenant des cannabinoïdes et leurs méthodes d'utilisation
EP3265096C0 (fr) Compositions ophtalmiques et leurs procédés d'utilisation
EP3576764A4 (fr) Compositions de vaccin peptidique kras et procédé d'utilisation
EP3558475A4 (fr) Tapis de course à utilisation assise et son procédé d'utilisation
EP3645013A4 (fr) Compositions et procédés pour inhiber l'expression de hmgb1
EP3922649C0 (fr) Anticorps anti-htra1 et leurs procédés d'utilisation
EP3526334A4 (fr) Variants de l'endonucléase tgfbéta r2, compositions et procédés d'utilisation
EP3534710A4 (fr) Compositions d'enrobage et leurs procédés d'utilisation
EP3448876C0 (fr) Mutéines de streptavidine et méthodes d'utilisation associées
EP3518910A4 (fr) Compositions de midodrine et leurs procédés d'utilisation
EP3568469A4 (fr) Compositions de cellules car-t dirigées contre hla-dr et leurs procédés de fabrication et d'utilisation
EP3727347A4 (fr) Compositions d'hydrochlorure de midodrine à libération prolongée et procédés d'utilisation

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200507

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PAEZ-ESPINO, DAVID

Inventor name: HARRINGTON, LUCAS B.

Inventor name: BURSTEIN, DAVID

Inventor name: DOUDNA, JENNIFER A.

Inventor name: BANFIELD, JILLIAN F.

Inventor name: CHEN, JANICE S.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40036150

Country of ref document: HK

A4 Supplementary search report drawn up and despatched

Effective date: 20210715

RIC1 Information provided on ipc code assigned before grant

Ipc: C12N 9/22 20060101AFI20210709BHEP

Ipc: C12Q 1/6809 20180101ALI20210709BHEP

Ipc: C12Q 1/6816 20180101ALI20210709BHEP

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230517

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20240201

TPAC Observations filed by third parties

Free format text: ORIGINAL CODE: EPIDOSNTIPA